Top 10 Psilocybin Papers for Safety & Risk Management

This paper puts safety at the centre: what can go wrong, who may be at higher risk, and what safeguards research or clinical practice needs. It helps balance enthusiasm for the intervention with the screening, monitoring, and follow-up questions that determine whether use is responsible. It is a useful counterweight to efficacy-focused papers because it keeps attention on screening, monitoring, and the conditions under which treatment can be used responsibly. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating psilocybin safety and risk management as a single settled topic.

The authors developed and validated the Challenging Experience Questionnaire (CEQ) to characterise acute adverse psychological reactions to psilocybin mushrooms, identifying seven reproducible factors — grief, fear, death, insanity, isolation, physical distress and paranoia. Factor scores correlated with perceived difficulty, meaningfulness, spiritual significance and changes in well‑being, and the factor structure was consistent across gender and prior anxiety or depression, providing a tool for future study of predictors and outcomes of challenging psychedelic experiences.

The open-label feasibility study showed that psilocybin-assisted group therapy was safe and effective for the treatment of demoralization in older long-term AIDS survivors. It is a useful counterweight to efficacy-focused papers because it keeps attention on screening, monitoring, and the conditions under which treatment can be used responsibly. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating psilocybin safety and risk management as a single settled topic.

An international web-based survey of people with self-reported bipolar disorder who had used psilocybin found that about one-third experienced new or worsened symptoms (notably mania, sleep disturbance and anxiety), while emergency medical attendance was uncommon and participants overall rated psilocybin as more helpful than harmful. The authors conclude these subjective benefits warrant clinical trials in bipolar disorder but emphasise trials must include careful monitoring because bipolar symptoms may emerge or intensify after use. It is a useful counterweight to efficacy-focused papers because it keeps attention on screening, monitoring, and the conditions under which treatment can be used responsibly.

In a mock‑MRI environment, slow intravenous administration of up to 2 mg psilocybin in healthy, hallucinogen‑experienced volunteers produced short‑lived, typical drug effects that were psychologically and physiologically well tolerated. The findings support the feasibility of conducting fMRI studies with psilocybin under appropriate care. It is a useful counterweight to efficacy-focused papers because it keeps attention on screening, monitoring, and the conditions under which treatment can be used responsibly. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating psilocybin safety and risk management as a single settled topic.

This pooled analysis of three randomised crossover studies evaluates the safety pharmacology of psilocybin. Psilocybin induced stronger effects at higher doses, with 25 mg and 30 mg doses showing increased anxiety. However, overall, psilocybin appeared safe in terms of acute psychological and physical harm, with no serious adverse reactions reported, suggesting its potential safety for controlled research settings. It is a useful counterweight to efficacy-focused papers because it keeps attention on screening, monitoring, and the conditions under which treatment can be used responsibly.

In a pilot randomised controlled trial of people with alcohol use disorder, viewing a nature-themed "Visual Healing" video during preparation and the ascent/descent phases of 25 mg psilocybin sessions was feasible, safe and well tolerated. Compared with standard procedures (eyeshades and music), Visual Healing attenuated peak post‑psilocybin blood pressure increases while producing similar psychedelic effects and reductions in alcohol use. It is a useful counterweight to efficacy-focused papers because it keeps attention on screening, monitoring, and the conditions under which treatment can be used responsibly.

In an open-label proof-of-concept trial, psilocybin-assisted therapy was well tolerated in adults with fibromyalgia, producing only transient elevations in blood pressure/heart rate and non-serious post-dose headaches. Participants showed clinically meaningful improvements in pain severity, pain interference and sleep disturbance one month after treatment, supporting progression to larger randomised controlled trials. For readers, the value is not just the result but the study design: it shows how psilocybin safety and risk management performs when tested under more structured clinical conditions.

A systematic review of published case reports identified 17 cases suggesting psilocybin (and related psychedelics) can precipitate manic episodes in people with bipolar disorder, indicating a real but poorly quantified risk. The authors conclude that, despite limited data, carefully controlled trials using modern set-and-setting safeguards and targeting lower-risk groups. That makes it useful as a map of psilocybin safety and risk management: it shows where evidence clusters, where the field is thin, and which claims need more cautious reading. Together with the other papers here, it connects the compound-specific evidence to the clinical question rather than treating psilocybin safety and risk management as a single settled topic.

In a Phase 2, non-randomised open-label trial of people with PTSD, a single 25 mg dose of psilocybin administered with psychological support was generally well tolerated with no serious adverse events and mostly transient side-effects, and was associated with large, clinically meaningful reductions in PTSD symptoms and improvements in functioning and quality of life sustained to 12 weeks. These results indicate single-dose psilocybin may be safe and potentially efficacious for PTSD, warranting further controlled investigation. For readers, the value is not just the result but the study design: it shows how psilocybin safety and risk management performs when tested under more structured clinical conditions.